1. Kimberg D, Aguirre G, Lease J, D'Esposito M. Cortical effects of bromocriptine, a D-2 dopamine receptor agonist, in human subjects, revealed by fMRI. Hum Brain Mapp. 2001. 12:246–257.
2. Honey G, Bullmore E, Soni W, Varatheesan M, Williams S, Sharma T. Differences in frontal cortical activation by a working memory task after substitution of risperidone for typical antipsychotic drugs in patients with schizophrenia. Proc Natl Acad Sci USA. 1999. 96:13432–13437.
3. Braus D, Ende G, Weber-Fahr W, et al. Antipsychotic drug effects on motor activation measured by functional magnetic resonance imaging in schizophrenic patients. Schizophr Res. 1999. 39:19–29.
4. Loubinoux I, Boulanouar K, Ranjeva J-P, et al. Cerebral functional magnetic resonance imaging activation modulated by a single dose of the monoamine neurotransmission enhancers fluoxetine and fenozolone during hand motor tasks. J Cereb Blood Flow Metab. 1999. 19:1365–1375.
5. Goldstein L, Coviello A, Miller G, Davis J. Norepinephrine depletion impairs motor recovery following sensorimotor cortex injury in the rat. Restor Neurol Neurosci. 1991. 3:41–47.
6. Goldstein L. Common drugs may influence motor recovery after stroke. Neurology. 1995. 45:865–871.
7. Gubitz G, Sandercock P, Counsell C. Antiplatelet therapy for acute ischemic stroke. The Cochrane Library. 2000. (Issue 1):Oxford:
8. Tokumaru S, Yoshikai T, Uchino A, Matsui M, Kuroda Y, Kudo S. Technetium-99m-ECD SPECT in antiphospholipid antibody syndrome: a drastic improvement in brain perfusion by antiplatelet therapy. Eur Radiol. 2001. 11:2611–2615.
9. Chan F, Ching J, Hung L, et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. New Engl J Med. 2005. 352:238–244.
10. Herbert JM, Savi P. P2Y12, a new platelet ADP receptor, target of clopidogrel. Semin Vasc Med. 2003. 3:113–122.
11. Friston K, Holmes A, Worsley K, Poline J, Frith C, Frackowiak R. Statistical parametric paps in functional imaging: a general linear approach. Hum Brain Mapp. 1995. 2:189–210.
12. Evans A, Collins D, Mills S, Brown E, Kelly R, Peters T. 3D statistical neuroanatomical models from 305 MRI volumes. Proc IEEE-Nucl Sci Symp Med Imaging. 1993. 1813–1817.
13. Talairach J, Tournoux P. Co-Planar Stereotaxic Atlas of the Human Brain. 1988. New York: Thieme.
14. Hochberg Y, Tamhane A. Multiple comparisons procedures. 1987. New York: Wiley.
15. Worsley K, Marrett S, Neelin P, Vandal A, Friston K, Evans A. A unified statistical approach for determining significant voxels in images of cerebral activation. Hum Brain Mapp. 1996. 4:58–73.
16. Mintzer M, Griffiths RR. Acute dose-effects of scopolamine on false recognition. Psychopharmacology. 2001. 153:425–433.
17. Bozzali M, MacPherson SE, Dolan RJ, Shallice T. Left prefrontal cortex control of novel occurrences during recollection: a psychopharmacological study using scopolamine and event-related fMRI. Neuroimage. 2006. 33:286–295.
18. Hasbroucq T, Rihet P, Blin O, Possamai C. Serotonin and human information processing: fluvoxamine can improve reaction time performance. Neurosci Lett. 1997. 229:204–208.
19. Weisskoff R, Zuo C, Boxerman J, Rosen B. Microscopic susceptibility variation and transverse relaxation: theory and experiment. Magn Reson Med. 1994. 31:601–610.
20. Lee S-P, Silva A, Ugurbil K, Kim S-G. Diffusion-weighted spin-echo fMRI at 9.4T: microvascular/tissue contribution to BOLD signal change. Magn Reson Med. 1999. 42:919–928.